The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) was held from 23-26 February in Seattle, Washington.
CROI is the most important annual scientific and medical HIV conference. This year the conference opened with important news on oral pre-exposure prophylaxis (PrEP), including the PROUD and IPERGAY studies, topical PrEP and other HIV prevention options – including research to reduce mother to child transmission. Other key sessions included HIV-related complications, antiretrovirals in the pipeline and HIV pathogenesis – especially in the context of cure research.
Abstracts for each study are available in a searchable online database and some posters are available to download as PDF files.
All plenary lectures and oral presentations are online as webcasts.
Articles included in this issue of HTB are:
- Pipeline ART: tenofovir alafenamide (TAF)
- Pipeline ART: maturation inhibitors and an attachment inhibitor
- No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil
- PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds
- “On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use
- Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel
- Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 >500 cells/mm3
- Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART
- Three drug ART best for preventing vertical transmission to infants: results from the PROMISE study
- 3 in 5 breastfeeding women with viral load >1,000 copies/mL are undiagnosed in Kenya, Malawi and South Africa
- Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group
- Weekend off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study
- Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART
- Lopinavir/ritonavir in young children is superior to nevirapine after five years: results from long term follow up of IMPAACT P1060
- Long-term safety and efficacy of tenofovir in children
- UK case of HIV remission: ten years off-ART in patient with prior progression and treated during seroconversion